Established in July 2008 with a research base in Oxford, UK and a clinical base in Philadelphia, US, Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune undertakes all of its own research and development using proprietary T cell receptor engineering technology co-developed with its sister company Immunocore Ltd (formerly Avidex/MediGene) and exclusively licensed for T cell therapy. Backed by private investors, Adaptimmune is now in the clinic in the US, in multiple cancer indications with its engineered TCR to the NY-ESO-1/LAGE-1 cancer testis antigen.
Adaptimmune’s Mission Statement
Adaptimmune’s mission is to develop disruptive therapy for serious disease using engineered T cells. The Company’s core technology is the development of affinity-enhanced T cell receptors (TCR) for use in adoptive T cell therapy.
The Adaptimmune product is a T cell expressing a modified TCR to recognize a tumour antigen (epitope) associated with a HLA molecule.